Baricitinib is being currently evaluated in a phase I/II basket trial in 20 patients with MCI, mild AD or Amyotrophic Lateral Sclerosis who must have elevated levels of the inflammatory cytokine CCL2 in CSF (NCT05189106). The gene discussed is CCL2; the disease is amyotrophic lateral sclerosis.